Basket cover image
17 handpicked stocks

Chipmakers Capitalizing On Intel's Pivot

Intel is undergoing a major restructuring, including significant layoffs and scaling back investments in new chip factories. This strategic pivot could create opportunities for its competitors to capture market share and expand their own manufacturing capabilities.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+7

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जुलाई 25

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

NVDA

NVIDIA Corporation

NVDA

Current price

$175.64

Leading AI chip designer positioned to capture additional market share as Intel scales back investments.

TSM

Taiwan Semiconductor Manufacturing Co.

TSM

Current price

$232.70

World's largest contract chip manufacturer that could absorb production capacity as Intel reduces factory investments.

AVGO

Broadcom Inc.

AVGO

Current price

$294.91

Diversified semiconductor company well-positioned to benefit from Intel's reduced competitive pressure.

About This Group of Stocks

1

Our Expert Thinking

Intel's major restructuring, including 15% workforce cuts and canceled factory investments, creates a significant opportunity in the semiconductor market. When a dominant player contracts, it often opens doors for competitors to capture market share, talent, and production capacity that was previously locked up.

2

What You Need to Know

This group spans the entire semiconductor ecosystem - from chip designers and manufacturers to foundries and equipment suppliers. It's an event-driven investment theme that focuses on companies positioned to benefit from Intel's strategic pullback and the resulting market dynamics.

3

Why These Stocks

These companies were handpicked by professional analysts as the most likely beneficiaries of Intel's pivot. They include direct competitors who can absorb market demand, foundries that can take on additional production, and equipment suppliers who may see increased orders as rivals expand operations.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+17.45%

Group Performance Snapshot

17.45%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 17.45% over the next year.

13 of 17

Stocks Rated Buy by Analysts

13 of 17 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🎯

Market Share Up for Grabs

Intel's workforce cuts and canceled investments create a rare opportunity for competitors to capture significant market share. When a major player steps back, the winners often emerge quickly.

Talent and Capacity Shift

With 15% of Intel's workforce being let go, rival companies can attract top semiconductor talent while also absorbing production capacity that's becoming available.

🚀

Equipment Suppliers Win Too

As Intel's competitors expand to fill the gap, companies that make semiconductor manufacturing equipment and materials could see a surge in new orders and contracts.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.